Lysophosphatidylcholines

Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL) . Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis[1][2][3][4].

Product Specifications

CAS Number

[9008-30-4]

UNSPSC

12352200

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; ERK; Interleukin Related; p38 MAPK

Type

Biochemical Assay Reagents

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lysophosphatidylcholines.html

Purity

99.0

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 100 mg/mL (ultrasonic) |Methanol : 25 mg/mL (ultrasonic)

Smiles

[Lysophosphatidylcholines]

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim E A, et al. Lysophosphatidylcholine induces endothelial cell injury by nitric oxide production through oxidative stress [J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2009, 22 (4) : 325-331.|[2]Liu-Wu Y, et al. Lysophosphatidylcholine induces the production of IL-1β by human monocytes [J]. Atherosclerosis, 1998, 137 (2) : 351-357.|[3]Takahashi M, et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism [J]. Atherosclerosis, 2002, 161 (2) : 387-394.|[4]Yan J J, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis [J]. Nature medicine, 2004, 10 (2) : 161-167.